Syndecan-4 is a heparan sulfate proteoglycan that is widely expressed in the vascular wall and as a cell surface receptor, modulates events relevant to acute tissue repair, including cell migration and proliferation, cell-substrate interactions, and matrix remodeling. While syndecan-4 expression is regulated in response to acute vascular wall injury, its regulation under chronic pro-atherogenic conditions, such as that characterized by prolonged exposure to oxidized lipids has not been defined.
INTRODUCTION
The syndecans are a family of transmembrane heparan and chondroitin sulfate proteoglycans involved in cell-matrix signaling (9, 40, 59 ). There are 4 members in mammals, syndecan 1, 2 (fibroglycan), 3 (N-syndecan), and 4 (ryudocan) (3) . Syndecans are found on all adherent cells where along with the glypicans they serve as the primary source of cell surface heparan sulfate. They affect cell growth and attachment to the extracellular matrix through covalently bound heparan sulfate chains, which act as coreceptors for growth factors such as bFGF and VEGF and bind to ECM components such as fibronectin and collagen (27, 54, 56) .
Syndecans also regulate lipid uptake through binding and internalization of lipoprotein lipaseenriched LDL particles (14) .
Syndecan-4 has several features unique among the syndecan proteoglycan family. The ectodomain of syndecan-4 has a cell binding site for an unknown cell surface ligand, thus enabling this proteoglycan to modulate cell-cell adhesion (31, 48). Additionally, syndecan-4 also contains a protein kinase C (PKC) binding site on its cytoplasmic tail and clustering of syndecan-4 promotes PKC activation (38) . Furthermore, syndecan-4 is found in focal adhesion sites, where it contributes to the structural and signaling functions of this macromolecular complex and may modulate cell-matrix interactions (10, 55) . For example, increased expression of syndecan-4 may diminish cell motility (28).
Atherosclerosis is a chronic inflammatory disease marked by aberrations in cell migration, proliferation, and LDL internalization, among other factors (29) . 29 Changes in syndecan-4 expression are known to alter these cellular functions, yet little is known about the regulation of syndecan-4 under pro-atherogenic conditions (14, 28, 54) . Syndecan-4 is highly regulated in other inflammatory conditions such as ischemic myocardial injury, dermal wound 4 repair, as well as arterial balloon injury (8, 15, 25) . In this regard, we postulated that syndecan-4 expression would likely be regulated by factors that contribute to atherosclerotic lesion formation.
Considerable evidence has confirmed that prolonged exposure to oxidatively modified low density lipoproteins (oxLDL), as well as its lipid components can lead to atherosclerotic plaque formation. HPODE (13-hydroperoxy-9,11-octadecadienoic acid) and HODE (13- hydroperoxy-10,12-octadecadienoic acid) are the oxidized products of linoleic acid, the major oxidizable fatty acid in LDL, and have been detected in oxidized LDL and atherosclerotic plaques (17, 46) . HPODE is known to regulate the expression of catalase, ICAM, HO-1, eNOS, and perlecan, and is a recognized smooth muscle cell mitogen (1, 13, 33, (41) (42) (43) . We report herein that expression of syndecan-4 mRNA and protein in vascular smooth muscle cells are controlled by HPODE using a signaling pathway dependent upon both intracellular hydrogen peroxide generation and the activation of p42/p44 MAPK. Furthermore HPODE increases the amount of syndecan-4 ectodomains released into the media. While not the focus of this report, it is conceivable that altered patterns in syndecan-4 expression and shedding contributes to proatherogenic cell behavior promoted by the presence of oxidized lipids within the arterial wall.
METHODS

Cell Culture
Rat aortic smooth muscle cells (RASM) were isolated from male Sprague-Dawley rats (4 to 6 weeks old, 200g) (53) . Rats were anesthetized with ether and the descending aorta harvested. Adventitia was mechanically removed after treatment with 0.4 mg/mL of collagenase and the endothelium scraped off of the opened aorta. The media was then minced and incubated with 0.7 mg/mL collagenase and 1 mg/mL elastase (Worthington Biochemical Products, Lakewood NJ). Cells were cultured in DMEM with 4.5g/L glucose (Gibco BRL), 10% FBS (Hyclone Laboratories, Logan UT), 100 U/L penicillin, 100 µg/L streptomycin, and 10 U/L amphotericin B. Smooth muscle cells (SMC) were characterized with immunostaining using SMC specific myosin antibodies and SMC specific actin antibodies (Sigma), with greater than 95% of cells exhibiting positive staining. Cells were then subcultured in DMEM with 1 g/L glucose, 10% FBS, 100 U/L penicillin, 100 µg/L streptomycin, and 10 U/L amphotericin B.
Experiments were performed on passage 6 and 7 cells that had been quiesced for 24 hrs in Ham's F12 media with 0.4% FBS. Although similar results were observed with DMEM, Ham's F12 was preferred for our investigations since it contains lower amounts of antioxidants and higher amounts of metals.
Human aortic smooth muscle cells (HSMC) were purchased from Clonetics and cultured in Clonetics' SMG media. Experiments were performed on passage 8 and 9 cells that had been quiesced for 24 hrs in Clonetics SMB media with 0.4% FBS. DRB (5,6-dichloro-1-β-Dribofuranosylbenzimidazole) was obtained from Sigma (St. Louis, MO).
Preparation and measurement of HPODE
HPODE was prepared by oxidation of linoleic acid using lipoxygenase. Briefly, 0.4 mM linoleic acid in PBS was incubated with 700 U soybean lipoxygenase at 37ºC until the reaction was complete as monitored by diene absorbance at 235 nm. HPODE was then purified using ether extraction, resuspended in ethanol, and concentration determined using 235 nm absorbance (ε = 2.52x10
) or by a leucomethylene blue assay using commercial HPODE as a control.
Leucomethylene blue reagent was prepared by dissolving benzoyl leuco methylene blue (TCI America; Portland, OR) in DMF to a concentration of 0.6 mg/mL, followed by addition of 1.4%
Triton X-100, 55 µg/mL hemoglobin, and 0.05 M potassium phosphate pH 5 in a 1:12.5 ratio.
To determine the stability of HPODE in the presence of cells, Ham's F12 media with or without 60 µM HPODE was incubated at 37ºC with confluent cells. At various times, aliquots of the media were incubated with leucomethylene blue reagent for 15 min and measured at 660 nm. Within 1 hr the HPODE was completely consumed or reduced by cellular components.
13S-HODE was obtained from Sigma (St. Louis, MO).
Ribonuclease protection assay
Cells were lysed in 1 mL Triazol reagent (Gibco BRL) and RNA extracted as recommended by the manufacturer. RNA probes radiolabeled with 32 P-UTP (Amersham) were synthesized using the Promega Riboprobe T7 system from pPMG/glyceraldehydes-4 phosphate dehydrogenase (GPDH; Pharmigen, rat and human), pTRI-RNA-28S (Ambion), PCDNA 3.1 (+)/rAsyndecan-4, or PCR hAsyndecan-4. RNA samples (10 µg) were hybridized overnight at 45ºC to respective probes using the Ambion RPAII kit, digested with RNAase, and precipitated.
RNA samples were then separated on a 5% polyacrylamide, 8 M urea, TBE gel and exposed to 7 film at -80ºC. Levels of RNA were quantified by densitometry using IP Lab Spectrum Plus (Scanalytics Inc., Fairfax, VA).
Western blotting
Polyclonal antibodies against the cytoplasmic (antibody 1423) and extracellular (antibody 1420) domains of rat syndecan-4 were a generous gift of Dr. Nicholas Shworak. A monoclonal antibody raised against human syndecan-4 (antibody 8G3) was a generous gift of Dr. Guido David. All secondary antibodies were from Jackson Laboratories (West Grove, PN).
Confluent cells were lysed in 20 mM Tris pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 10 mM EDTA, 1 mM PMSF, 10 mM NEM, 1 µg/ml pepstatin A, and 0.5 µg/ml leupeptin at 4ºC.
Proteoglycans were then isolated on a DEAE-Sephadex column equilibrated with 20 mM sodium acetate pH 5, 200 mM NaCl, 6 M urea, 0.5% Triton X-100, 1 mM EDTA, 1 mM sodium sulfate and eluted with 20 mM sodium acetate pH 5, 1 M NaCl, 6 M urea, 0.5% Triton X-100, 1 mM EDTA, and 1 mM sodium sulfate. Proteogycans were precipitated by incubating the eluant with 4 volumes of 4ºC ethanol and 2 nmol dextran sulfate for 2 hrs at 4ºC followed by centrifugation at 12,000 g for 1 hour. The proteoglycans were resuspended in water and the amount of protein quantified using a Bradford assay (Biorad, Inc.) with albumin as a standard. 
Detection of phosphorylated ERK
Confluent RASMs were treated with 20 µM HPODE for various times and then lysed by treatment with 20 mM Tris pH 7.4, 150 mM NaCl, 0.5% Triton X 100, 10 mM EDTA, 0.1 mM PMSF, 0.5 ug/ml leupeptin, 10 ug/ml pepstatin A, and 5 ug/ml aprotinin A for 15 min at 4ºC.
Non-soluble protein was removed by centrifugation at 16,000 g for 10 min at 4ºC. Equal amounts of protein were then resolved by 12% SDS-PAGE, transferred to a nitrocellulose membrane, and probed with antibodies to phosphorylated forms of p44 and p42 (Cell Signaling 9 Technology, Inc. Beverly MA), followed by HRP-conjugated anti-mouse IgG antibodies. As a control, antibodies were removed with 62.5 mM Tris pH 6.7, 2% SDS, and 100 mM 2-mercaptoethanol and the membrane reprobed with antibodies that recognize all forms of p44 and p42 followed by HRP-conjugated anti-rabbit IgG antibodies. Total and phosphorylated p44/p42
were quantified with chemiluminescence and densitometry.
Statistics
Data were analyzed by Student's t-test or one-way ANOVA to compare differences among average values obtained from within groups. When the ANOVA indicated a significant difference among groups, as indicated by the F statistic, comparison among means was performed using Tukey's F-test. Significance was accepted at p < 0.05. Unless otherwise noted, data is presented as means ± SE of at least 4 independent experiments.
RESULTS
HPODE induces syndecan-4 mRNA expression
To investigate the regulation of syndecan-4 under pro-atherogenic conditions, oxidized products of linoleic acid were incubated with arterial smooth muscle cells. The oxidized free fatty acid HPODE caused a dose-dependent increase in syndecan-4 mRNA ( Fig. 1 A,B) . The effect was transient, with a maximum response observed at 2-3 hrs. A lack of cell necrosis over the experimental dose range of HPODE was demonstrated using trypan blue staining, though at concentrations >30 µM HPODE cell death was visibly evident. Leucomethylene blue analysis, used to quantify the amount of HPODE in the media, revealed that in the presence of cells HPODE was completely consumed or reduced within 1 hr.
Most preparations of HPODE contain at least some HODE, although leucomethylene blue analysis demonstrated that >90% of the oxidized lipid was HPODE at the time it was added to the cells. To determine whether HODE was the active element causing increased syndecan-4 mRNA expression, cells were exposed to purified 13-S HODE. While HODE did produce a dose-dependent increase in syndecan-4 mRNA, it was less pronounced than HPODE (Fig. 1C) .
Neither linoleic acid (20 µM) nor ethanol (the vehicle for HPODE) altered syndecan-4 mRNA expression (data not shown).
The effect of HPODE on syndecan-4 mRNA did not require de-novo protein synthesis.
Inhibition of protein synthesis prior to HPODE exposure by cyclohexamide did not attenuate enhanced syndecan-4 mRNA levels (Fig. 1D) . Rather cyclohexamide augmented the HPODEdependent rise of syndecan-4 mRNA, a trait typical among early response genes and one that has been previously demonstrated for syndecan-4 (8, 39, 52).
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The observed increase in mRNA induced by HPODE could be attributed at least in part to stabilization of the syndecan 4 transcript. This was demonstrated by use of transcription inhibitor, DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole), which was added to the culture medium after exposure to HPODE (Fig. 2) . A logarithmic fit of the data established that the half-life of syndecan 4 mRNA increased from 1.4 hr to 6.2 hr after 2 hr HPODE exposure (p < 0.01). However after 18 hrs HPODE exposure, there was no difference in the stability of the syndecan 4 transcripts as compared to control cells.
Generation of hydrogen peroxide is necessary but not sufficient for HPODE-mediated augmentation of syndecan-4 mRNA expression HPODE generates intracellular oxidant stress and therefore may influence syndecan-4 expression through an oxidant-sensitive transcription factor. DCFDA fluorescence confirmed that HPODE-treated cells were exposed to increased oxidative stress (Fig. 3A) . Catalase, a scavenger of hydrogen peroxide, has been shown to protect cells against HPODE-induced apoptosis (45) . Since catalase does not react directly with HPODE, this data has suggested that HPODE stimulates the production of intracellular hydrogen peroxide, possibly by the peroxisome during HPODE degradation. Therefore, in order to determine whether hydrogen peroxide production is required for HPODE-signaling, cells were either exposed to antioxidants such as catalase or N-acetylcysteine (NAC) to diminish hydrogen peroxide levels or treated with aminotriazol, an inhibitor of intracellular catalase, to enhance hydrogen peroxide levels. Cells pre-loaded with catalase or NAC prior to exposure to HPODE did not exhibit as large of an increase in syndecan-4 mRNA as cells treated with HPODE alone. Addition of aminotriazole produced a significant enhancement of the HPODE effect (Fig. 3B) . Furthermore the addition of butyric acid, another compound shown to produce hydrogen peroxide when catabolized by the 12 peroxisome, also increased syndecan-4 expression in vascular SMCs. These results support the notion that intracellular production of hydrogen peroxide is a mediator of the HPODE-induced increase in syndecan-4 mRNA. Notably, addition of extracellular hydrogen peroxide in the concentration range of 50 -200µM, either as a bolus or produced in situ with glucose oxidase, failed to alter syndecan-4 mRNA levels (data not shown).
Since the syndecan-4 promoter contains binding sites for NFκB, which may be activated by hydrogen peroxide or oxidized LDL, it was anticipated that NFκB would be a mediator of HPODE signaling (18, 30, 51) . To test this hypothesis, cells were treated with increasing doses of NFκB inhibitors, curcumin and lactacystin, prior to HPODE exposure. Both compounds failed to diminish the effect of HPODE on syndecan-4 (Fig. 4) . Thus, unlike TNF-α stimulation of syndecan-4 expression, HPODE-induced enhancement of syndecan-4 mRNA does not appear to rely on activation of NFκB (58).
Activation of ERK is required for HPODE-mediated upregulation of syndecan-4 mRNA Extracellular-Signal Receptor Kinase (ERK) has been shown to mediate EGF-dependent shedding of syndecan-4 in immortalized endothelial and epithelial cells (12) . To determine whether ERK activation was involved in the HPODE-dependent increase of syndecan-4 mRNA expression, ERK phosphorylation was examined using antibodies specific to the dualphosphorylated active forms of p44 and p42 ERK. Upon addition of HPODE, ERK was phosphorylated in a time-dependent manner (Fig. 5A ) that was abrogated by exposing the cells to catalase prior to HPODE exposure. Furthermore, treatment of cells with PD98059 or U0126, specific inhibitors of MEK1/2, prevented the rise of syndecan-4 mRNA after addition of HPODE (Fig. 5B) . SB203580, a specific inhibitor of p38 MAPK, was less effective. Addition of 13 hydrogen peroxide alone caused ERK phosphorylation (data not shown) (18, 57) , which suggests that HPODE is activating the ERK signal transduction pathway through production of intracellular hydrogen peroxide. Thus, HPODE-induced syndecan-4 mRNA expression appears to depend on intracellular hydrogen peroxide production that activates MEK1/2 to phosphorylate ERK.
HPODE signaling does not occur through PPAR
HPODE and HODE are known ligands for PPARγ receptors in smooth muscle cells (36, 47) . To determine whether the syndecan-4 mRNA response to HPODE was partially mediated through PPARγ, cells were exposed to two PPARγ agonists over a concentrations range that included the EC 50 values for PPARγ activation. Neither caused a significant increase in syndecan-4 mRNA, and 15-deoxy-Δ 12,14 -prostaglandin J 2 actually produced a dramatic decrease in mRNA (Fig. 6) . These results indicate that PPARγ receptors are not involved in the regulation of syndecan-4 mRNA by HPODE.
Syndecan-4 shedding is stimulated by HPODE
HPODE regulated syndecan-4 protein, as well as mRNA. Cellular syndecan-4 protein was measured in both rat and human SMCs by Western blot analysis of purified cellular proteoglycans. There was a marked decline in cellular syndecan-4 protein within 2 hrs following exposure to HPODE (Fig. 7A and B) ; though 24 hr after HPODE exposure protein concentrations began to recover. Shed syndecan-4 was detected in the culture media of HSMCs as early as 1 hour after treatment with HPODE, which likely accounts for the diminished cellular syndecan-4 concentrations (Fig. 7C) .
DISCUSSION
Syndecans are highly regulated during repair of cutaneous and arterial wounds, as well as in response to ischemic myocardial injury (8, 16, 25) . In a myocardial infarct model, syndecan-4 expression is predominant in newly formed granulation tissue (25) . Of note, delayed formation of granulation tissue and decreased angiogenesis has been observed after cutaneous injury in syndecan-4 -/-transgenic mice (11) . In this report, we have demonstrated using rat and human vascular SMC that syndecan-4 is also regulated by 13S-HPODE, an oxidized lipid present in oxidized LDL and atherosclerotic plaques. Though there is an initial enhancement of syndecan-4 mRNA expression upon HPODE exposure due in part to the stabilization of syndecan-4 mRNA, a persistent depression of both syndecan-4 mRNA and protein was subsequently observed. suggests that a potential role for SP1 may exist. Specifically, we observed that 15dPGJ 2 , which inhibits SP1 binding to DNA through the activation of PPARγ (50), reduced the expression of syndecan-4. Notably, recent studies suggest that HPODE causes a decrease in PPARγ activity by MAPK induced phosphorylation (19) , and thereby, in principle, could potentiate SP1 binding and perhaps, as a consequence, increased syndecan-4 expression. Nonetheless, 15dPGJ 2 has other biological functions besides the activation of PPARγ, which may be responsible for this effect. For example, 15dPGJ 2 has been shown to augment intracellular glutathione levels, and thus has an antioxidant effect similar to NAC. Although by itself NAC did not influence basal syndecan-4 levels, it did slightly inhibit the HPODE effect (Fig. 2B) . Of greater significance, 15dPGJ 2 also inhibits ubiquitin isopeptidase and thereby interferes with the proteosome pathway (35) . Indeed, we observed that lactacycstin, which also inhibits the proteosome pathway, caused a dramatic decrease in syndecan-4 mRNA levels (Fig. 3) . Therefore, further studies will be necessary to establish which supplementary factors, in addition to intracellular production of hydrogen peroxide and ERK activation, are involved in syndecan-4 regulation by HPODE.
It is unusual that the addition of extracellular hydrogen peroxide did not produce an increase in syndecan-4 mRNA despite the reliance of syndecan-4 regulation upon intracellular hydrogen peroxide production. Nonetheless, similar phenomena have been observed in other studies. For example TNF-α stimulation of NFκB in dermal fibroblasts was enhanced by addition of the catalase inhibitor aminotriazol, but NFκB activation was not observed upon the addition of extracellular hydrogen peroxide (23) . Therefore, it is possible that oxidantdependent pathway signaling requires the generation of high concentrations of hydrogen peroxide within a specific subcellular compartment that cannot be easily achieved by the addition of hydrogen peroxide to cell medium.
The diminished cellular levels of syndecan-4 protein observed after the exposure of SMCs to HPODE were due at least in part to loss of syndecan-4 into the media, a process termed shedding. Shed syndecan-4 was seen as early as 1 hr after the addition of HPODE prior to any changes in mRNA expression. Shedding of syndecan-4 is also reported to occur with EGF or thrombin-receptor activation, plasmin, heat shock, and osmotic stress and is known to occur in vivo, where the extracellular domain of syndecan-4 is found in dermal wound fluid (12, 49) . (21) . Heparan sulfates can also sequester within the extracellular matrix both growth factors and pro-inflammatory chemokines, such as RANTES, MCP-1, and IL-8 (24) . In the process, these factors are likely protected from heat, pH, and protease related degradation mechanisms and their ability to interact with cell bound receptors limited until their release by heparanase induced HS cleavage (22) . Shedding of the syndecan-4 ectodomain has not been studied in response to bFGF, PDGF, or TNF-α; compounds that are known to regulate syndecan-4 mRNA expression. Therefore, HPODE is the only compound, to date, that is known to regulate both syndecan-4 mRNA expression and ectodomain shedding.
It is also interesting to speculate that direct reduction in cell surface syndecan-4 levels produced by HPODE, in addition to syndecan shedding, may provide a second mechanism for altering cell behavior. Although additional investigations will be required to determine the physiological significance of HPODE-induced changes in syndecan-4 expression and shedding, in principle, this phenomenon might augment a variety of proatherogenic events that occur in response to oxidized lipids (4, 5, 34) . The release of syndecan ectodomains into the extracellular matrix of the vascular wall may well lead to an increase in protease activity, the proliferation of SMCs, and also assist in establishing chemotactic gradients for the recruitment of myofibroblasts, SMCs, and leukocytes (21, 22, 24, 26) . Moreover, SMC release of heparan sulfate-containing syndecan ectodomains could potentially increase the local retention of lipoprotein lipase-enriched LDL. It is conceivable that as a consequence of this effect, a positive feedback loop is created, whereby further oxidation of LDL is promoted that could lead to foam cell formation, as well as persistent changes in syndecan-4 expression (14, 32).
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A B FIGURE 5. HPODE regulation of syndecan-4 mRNA is dependent on ERK activation.
(A) Rat SMCs were incubated with or without 3000 U/ml catalase after which the cells were washed and exposed to 20 µM 13S-HPODE for various times. Cell lysates were collected as described in Methods and probed with antibodies for phosphorylated ERK and total ERK. (B) Rat SMCs were incubated for 1 hr with 20 µM PD98059, 300nM U0126, or 10 µM SB203580 followed by 20 µM 13S-HPODE for 3 hrs. RNA was then collected and probed for syndecan-4 and GAPDH mRNA using RPA. 
